MTOR and tuberous sclerosis: Of the 33 clinical studies that were relevant to mTOR inhibitor therapy in the patients with TSC, 22 were excluded: 16 studies were excluded as they did not include pediatric patients and six were excluded as they did not include outcomes of interest.